β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity
作者： Benedikt A. Aulinger , Torsten P. Vahl , Hilary E. Wilson-Pérez , Ron L. Prigeon , David A. D'Alessio
DOI: 10.1210/JC.2014-4009
关键词:
摘要: Context: Glucagon-like peptide-1 (GLP-1) is an insulinotropic factor made in the gastrointestinal tract that essential for normal glucose tolerance. Infusion of GLP-1 increases insulin secretion both diabetic and nondiabetic humans. However, degree to which people vary their β-cell sensitivity factors contributing this variability have not been reported. Objective: The objective was measure cohorts lean obese subjects across a broad range sensitivity. Methods: Insulin measured during clamped hyperglycemia (7.2 mmol/L) graded infusion young, healthy subjects, computed from rate (ISR) progressive plasma GLP-1. Results: All had fasting values <5.2 mm. were resistant compared group (homeostasis model assessment 2 resistance: obese, 2.6 ± 0.5; le...
oup.com
endocrine.org
sci-hub.se 参考文章(35)
Jonathan E. Campbell, Daniel J. Drucker, Pharmacology, physiology, and mechanisms of incretin hormone action Cell Metabolism. ,vol. 17, pp. 819- 837 ,(2013) , 10.1016/J.CMET.2013.04.008
K. Müssig, H. Staiger, F. Machicao, H.-U. Häring, A. Fritsche, Genetic variants affecting incretin sensitivity and incretin secretion Diabetologia. ,vol. 53, pp. 2289- 2297 ,(2010) , 10.1007/S00125-010-1876-8
Torsten P. Vahl, Breay W. Paty, Bradley D. Fuller, Ronald L. Prigeon, David A. D’Alessio, Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. The Journal of Clinical Endocrinology and Metabolism. ,vol. 88, pp. 1772- 1779 ,(2003) , 10.1210/JC.2002-021479
M A Nauck, M M Heimesaat, C Orskov, J J Holst, R Ebert, W Creutzfeldt, Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of Clinical Investigation. ,vol. 91, pp. 301- 307 ,(1993) , 10.1172/JCI116186
Richard D Carr, Marianne O Larsen, Katarina Jelic, Ola Lindgren, Jenny Vikman, Jens J Holst, Carolyn F Deacon, Bo Ahren, None, Secretion and Dipeptidyl Peptidase-4-Mediated Metabolism of Incretin Hormones after a Mixed Meal or Glucose Ingestion in Obese Compared to Lean, Nondiabetic Men. The Journal of Clinical Endocrinology and Metabolism. ,vol. 95, pp. 872- 878 ,(2010) , 10.1210/JC.2009-2054
S. A. Schäfer, K. Müssig, H. Staiger, F. Machicao, N. Stefan, B. Gallwitz, H. U. Häring, A. Fritsche, A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion Diabetologia. ,vol. 52, pp. 1075- 1082 ,(2009) , 10.1007/S00125-009-1344-5
Timothy James Kieffer, Joel Francis Habener, None, The glucagon-like peptides. Endocrine Reviews. ,vol. 20, pp. 876- 913 ,(1999) , 10.1210/EDRV.20.6.0385
E. V. Cauter, F. Mestrez, J. Sturis, K. S. Polonsky, Estimation of Insulin Secretion Rates from C-Peptide Levels: Comparison of Individual and Standard Kinetic Parameters for C-Peptide Clearance Diabetes. ,vol. 41, pp. 368- 377 ,(1992) , 10.2337/DIAB.41.3.368
D A D'Alessio, R Vogel, R Prigeon, E Laschansky, D Koerker, J Eng, J W Ensinck, Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. Journal of Clinical Investigation. ,vol. 97, pp. 133- 138 ,(1996) , 10.1172/JCI118380
M. Nauck, F. Stöckmann, R. Ebert, W. Creutzfeldt, Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. ,vol. 29, pp. 46- 52 ,(1986) , 10.1007/BF02427280